triamcinolone acetonide has been researched along with Wet Macular Degeneration in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 16 (94.12) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Fukuda, Y; Kashiwagi, K; Matsubara, M; Parikh, R; Sakurada, Y; Shigemoto, Y | 1 |
| Bolz, M; Eisenkölbl, S; Huf, W; Kiss, C; Munk, M; Sayegh, R; Schmidt-Erfurth, U; Simader, C; Sulzbacher, F | 1 |
| Lanzetta, P; Veritti, D | 1 |
| Boscia, F; Ciracì, L; Dayani, P; Flynn, HW; Furino, C; Mariotti, C; Sborgia, A; Tabandeh, H | 1 |
| Curcio, CA; Ooto, S; Sato, T; Spaide, RF; Suzuki, M; Vongkulsiri, S | 1 |
| Lim, JI; Niec, M; Wong, V | 1 |
| Busse, H; Gebauer, S; Koch, R; Schmidt, M; Uhlig, CE | 1 |
| Haeussler-Sinangin, Y; Koch, FH; Koss, MJ; Scholtz, S; Singh, P | 1 |
| Arcidiacono, B; Becerra, EM; Danzi, P; Gandolfo, F; Morescalchi, F; Nascimbeni, G; Semeraro, F | 1 |
| Bidot, ML; Bidot, S; Bron, A; Creuzot-Garcher, C; Malvitte, L | 1 |
| Ahmadieh, H; Daftarian, N; Homayouni, M; Piri, N; Riazi-Esfahani, M; Taei, R; Yaseri, M | 1 |
| Nakanishi, H; Nakata, I; Otani, A; Tsujikawa, A; Yamashiro, K; Yoshimura, N | 1 |
| Ceran, BB; Masket, S | 1 |
| Drobek-Słowik, M; Karczewicz, D; Krzystolik, K; Kubasik-Kładna, K; Mozolewska-Piotrowska, K | 1 |
| Augustin, AJ; Rizzo, S; Tetz, M | 1 |
| Fujiwara, A; Nitta, E; Shiraga, F; Shiragami, C; Shirakata, Y; Yamashita, A | 1 |
| Atili, A; Baraki, H; Feltgen, N; Geck, U; Hoerauf, H; Pustolla, N | 1 |
1 review(s) available for triamcinolone acetonide and Wet Macular Degeneration
| Article | Year |
|---|---|
Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Blindness; Choroidal Neovascularization; Combined Modality Therapy; Delayed-Action Preparations; Humans; Hyperthermia, Induced; Intravitreal Injections; Macular Degeneration; Photochemotherapy; Photosensitizing Agents; Porphyrins; Triamcinolone Acetonide; Vascular Endothelial Growth Factors; Verteporfin; Wet Macular Degeneration | 2011 |
2 trial(s) available for triamcinolone acetonide and Wet Macular Degeneration
| Article | Year |
|---|---|
One year results of a phase 1 study of the safety and tolerability of combination therapy using sustained release intravitreal triamcinolone acetonide and ranibizumab for subfoveal neovascular AMD.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Delayed-Action Preparations; Drug Therapy, Combination; Female; Follow-Up Studies; Glucocorticoids; Humans; Intravitreal Injections; Male; Middle Aged; Ranibizumab; Tomography, Optical Coherence; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration | 2015 |
Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Drug Therapy, Combination; Female; Fluorescein Angiography; Follow-Up Studies; Glucocorticoids; Humans; Intravitreal Injections; Male; Middle Aged; Prospective Studies; Retreatment; Tomography, Optical Coherence; Treatment Outcome; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration | 2011 |
14 other study(ies) available for triamcinolone acetonide and Wet Macular Degeneration
| Article | Year |
|---|---|
The combination therapy of subtenon triamcinolone acetonide injection and intravitreal brolucizumab for brolucizumab-related intraocular inflammation.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Drug Therapy, Combination; Humans; Intravitreal Injections; Male; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Subretinal Fluid; Triamcinolone Acetonide; Visual Acuity; Wet Macular Degeneration | 2021 |
Therapeutic interventions for macular diseases show characteristic effects on near and distance visual function.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Female; Follow-Up Studies; Glucocorticoids; Humans; Intravitreal Injections; Macular Edema; Male; Middle Aged; Ranibizumab; Reading; Recovery of Function; Tomography, Optical Coherence; Triamcinolone Acetonide; Uveitis; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration | 2013 |
Triple therapy for anti-vascular endothelial growth factor nonresponders in neovascular age-related macular degeneration: impact of different photodynamic therapy parameters.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Combined Modality Therapy; Female; Follow-Up Studies; Glucocorticoids; Humans; Intravitreal Injections; Male; Photochemotherapy; Photosensitizing Agents; Porphyrins; Ranibizumab; Tomography, Optical Coherence; Treatment Outcome; Triamcinolone Acetonide; Verteporfin; Visual Acuity; Wet Macular Degeneration | 2013 |
Endophthalmitis associated with intravitreal injections: office-based setting and operating room setting.
Topics: Ambulatory Surgical Procedures; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Endophthalmitis; Glucocorticoids; Humans; Incidence; Intravitreal Injections; Macular Edema; Operating Rooms; Ranibizumab; Retinal Vein Occlusion; Retrospective Studies; Triamcinolone Acetonide; Wet Macular Degeneration | 2014 |
Outer retinal corrugations in age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Basement Membrane; Bevacizumab; Female; Geographic Atrophy; Glucocorticoids; Humans; Intravitreal Injections; Male; Photochemotherapy; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retina; Retrospective Studies; Tissue Donors; Tomography, Optical Coherence; Triamcinolone Acetonide; Visual Acuity; Wet Macular Degeneration | 2014 |
Intravitreal treatment in patients with exudative age-related macular degeneration and visual acuity ≤ 0.05.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bevacizumab; Drug Therapy, Combination; Exudates and Transudates; Female; Glucocorticoids; Humans; Intravitreal Injections; Male; Middle Aged; Ranibizumab; Retrospective Studies; Subretinal Fluid; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration | 2015 |
Combined intravitreal pharmacosurgery in patients with occult choroidal neovascularization secondary to wet age-related macular degeneration.
Topics: Acetates; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Choroidal Neovascularization; Combined Modality Therapy; Drug Combinations; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Injections; Male; Middle Aged; Minerals; Pilot Projects; Prospective Studies; Sodium Chloride; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A; Visual Acuity; Vitrectomy; Vitreous Body; Wet Macular Degeneration | 2010 |
[Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Topics: Aged; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Bevacizumab; Choroidal Neovascularization; Endophthalmitis; Fluorescein Angiography; Follow-Up Studies; Glucocorticoids; Humans; Intravitreal Injections; Macula Lutea; Macular Edema; Photochemotherapy; Pigment Epithelium of Eye; Retinal Detachment; Retinal Hemorrhage; Retinal Perforations; Retrospective Studies; Subretinal Fluid; Tomography, Optical Coherence; Treatment Outcome; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Hemorrhage; Wet Macular Degeneration | 2011 |
VEGF gene polymorphism and response to intravitreal bevacizumab and triple therapy in age-related macular degeneration.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Combined Modality Therapy; Female; Genotype; Glucocorticoids; Humans; Intravitreal Injections; Male; Photochemotherapy; Polymorphism, Single Nucleotide; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration | 2011 |
Atypical case of ocular hemosiderosis: leopard cataract.
Topics: Aged, 80 and over; Cataract; Combined Modality Therapy; Female; Glucocorticoids; Hemosiderosis; Humans; Lens Capsule, Crystalline; Phacoemulsification; Photochemotherapy; Retinal Detachment; Retinal Hemorrhage; Triamcinolone Acetonide; Vitreous Hemorrhage; Wet Macular Degeneration | 2011 |
[Combined photodynamic therapy and intravitreal injection of triamcinolone acetonide in patients with wet form of AMD. Introductory report].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Male; Photochemotherapy; Photosensitizing Agents; Poland; Treatment Outcome; Triamcinolone Acetonide; Visual Acuity; Wet Macular Degeneration | 2011 |
Safety of submacular suprachoroidal drug administration via a microcatheter: retrospective analysis of European treatment results.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Catheters, Indwelling; Choroid; Drug Delivery Systems; Drug Therapy, Combination; Female; Fluorescein Angiography; Glucocorticoids; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Tomography, Optical Coherence; Triamcinolone Acetonide; Visual Acuity; Wet Macular Degeneration | 2012 |
One-year results of bevacizumab intravitreal and posterior sub-Tenon injection of triamcinolone acetonide with reduced laser fluence photodynamic therapy for retinal angiomatous proliferation.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Coloring Agents; Combined Modality Therapy; Female; Fluorescein Angiography; Glucocorticoids; Humans; Indocyanine Green; Injections; Intravitreal Injections; Male; Photochemotherapy; Recurrence; Retinal Neovascularization; Retreatment; Retrospective Studies; Tenon Capsule; Tomography, Optical Coherence; Treatment Outcome; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration | 2012 |
Posterior vitreous detachment following intravitreal drug injection.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Female; Follow-Up Studies; Fourier Analysis; Humans; Incidence; Intravitreal Injections; Macular Edema; Male; Microscopy, Acoustic; Middle Aged; Prospective Studies; Ranibizumab; Retinal Vein Occlusion; Tomography, Optical Coherence; Treatment Outcome; Triamcinolone Acetonide; Vitreous Detachment; Wet Macular Degeneration | 2013 |